Pulmatrix Inc PULM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.40
- Day Range
- $1.31–1.40
- 52-Week Range
- $1.18–4.96
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 3.65M
- Market Cap
- $4.86M
- Volume/Avg
- 56,137 / 26,848
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.pulmatrix.com
Valuation
|
Metric
|
PULM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.05 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PULM
|
|---|---|
Quick Ratio | 3.15 |
Current Ratio | 4.70 |
Interest Coverage | — |
Quick Ratio
PULM
Profitability
|
Metric
|
PULM
|
|---|---|
Return on Assets (Normalized) | −86.83% |
Return on Equity (Normalized) | −108.74% |
Return on Invested Capital (Normalized) | −100.25% |
Return on Assets
PULM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@#@wh<y | LOCK|$kXF | $135B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|jl?!>m | LOCK|#ksqd | $101B | |||
| Moderna Inc
MRNA
| LOCK|N%r@Bd@ | LOCK|l^ | $91B | |||
| argenx SE ADR
ARGX
| LOCK|snSz@%$ | LOCK|#GM | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Xcp&tq@ | LOCK|M<^ | $41B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&>!G^$$ | LOCK|w^?q | $30B | |||
| Incyte Corp
INCY
| LOCK|?rb<%< | LOCK|X$ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|p<^jDbz | LOCK|w!? | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$<M>KS | LOCK|tP&&n | $21B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&^?$v%f | LOCK|$L< | $15B |
United States